Forsythoside A (FA) (Figure 4e) treatment is known for its anti-AD properties exerted by the modulation of ferroptosis and inflammation targeting the activation of the Nrf2/GPX4 axis [116]. Here, GPX4 is linked to Alzheimer disease.